My worst case scenario with Ronin was that they might know of a manufacturing problem. I have seen biological manufacturers shut down for months while they work through FDA compliance.
Now that Lias and team came through today with contracts (just as they said they would), and a modular expansion that will start generating incremental revenue by September, I can toss out the worst case for the Ronin sell.
Which takes me right back to this was isolated to Ronin (as Tappan maintained their position) and probably a cash raise for taxes. I would not be the least bit surprised if they were buying back in today.
These guys saved the Company, and have begun a nice turnaround, regardless what some of the constant naysayers post.
Market Data 
Markets 
AI
